drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An intravenous glyco-humanized polyclonal antibody (biologic immunotherapy) engineered with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function; expected to mediate tumor cell killing via ADCC, ADCP, and CDC in advanced/metastatic solid tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Polyclonal
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Glyco‑humanized polyclonal antibody that binds multiple tumor epitopes and is engineered with human-like Fc glycosylation to enhance Fc effector function and reduce immunogenic carbohydrates; kills tumor cells via Fc-dependent mechanisms including ADCC (via Fcγ receptor–bearing NK cells), ADCP (macrophages), and CDC (classical complement activation).
drug_name
XON7
nct_id_drug_ref
NCT06154291